Quick Read GLP-1 market growth is fueling Viking Therapeutics‘ (VKTX) momentum with VK2735 in Phase 3 and VK2809’s NASH ...

All this means that Viking is a great biotech buy -- its candidate is promising, you can benefit from getting in on the dip, and momentum has been picking up. But you don't have to rush to scoop up ...

Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nordisk.

Eli Lilly holds the lead position in the weight management market right now. But Viking Therapeutics is working on a candidate that could be a game-changer. Viking is a riskier-than-average stock, but ...

Financial giants have made a conspicuous bullish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics VKTX revealed 12 unusual trades. Delving into the details, we ...

JP Morgan analyst Matthew Boss reiterated an Overweight rating on the shares of Viking Holdings Ltd (NYSE:VIK) and raised the price target to $58 from $50. From 2017 to 2019, VIK’s pre-pandemic annual ...

Viking Therapeutics has promising clinical developments in obesity, NASH/MASH, and X-ALD, but its stock fell 50% due to broader GLP-1 market concerns. Despite Eli Lilly's Q4 miss, the long-term ...

Viking aims to enter the billion-dollar weight loss drug market. Early last year, Viking announced results from a phase 2 trial of its injectable weight loss drug candidate and saw its stock surge ...